855 related articles for article (PubMed ID: 30415318)
1. Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.
Grativvol RS; Cavalcante WCP; Castro LHM; Nitrini R; Simabukuro MM
Curr Oncol Rep; 2018 Nov; 20(11):92. PubMed ID: 30415318
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic epilepsy.
Serafini A; Lukas RV; VanHaerents S; Warnke P; Tao JX; Rose S; Wu S
Epilepsy Behav; 2016 Aug; 61():51-58. PubMed ID: 27304613
[TBL] [Abstract][Full Text] [Related]
3. [Paraneoplastic neurological syndromes : A current summary].
De Simoni D; Höftberger R
Internist (Berl); 2018 Feb; 59(2):151-158. PubMed ID: 29327271
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune Epilepsy.
Gaspard N
Continuum (Minneap Minn); 2016 Feb; 22(1 Epilepsy):227-45. PubMed ID: 26844739
[TBL] [Abstract][Full Text] [Related]
5. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
6. Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection.
Scotton WJ; Karim A; Jacob S
Methods Mol Biol; 2019; 1941():225-255. PubMed ID: 30707437
[TBL] [Abstract][Full Text] [Related]
7. [Neurological syndromes, encephalitis].
Yamamoto T; Tsuji S
Gan To Kagaku Ryoho; 2010 Jun; 37(6):995-1005. PubMed ID: 20567100
[TBL] [Abstract][Full Text] [Related]
8. Movement disorders in paraneoplastic and autoimmune disease.
Panzer J; Dalmau J
Curr Opin Neurol; 2011 Aug; 24(4):346-53. PubMed ID: 21577108
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated disorders.
Höftberger R; Lassmann H
Handb Clin Neurol; 2017; 145():285-299. PubMed ID: 28987176
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic autoimmune movement disorders.
Lim TT
Parkinsonism Relat Disord; 2017 Nov; 44():106-109. PubMed ID: 29097081
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic movement disorders.
Popławska-Domaszewicz K; Florczak-Wyspiańska J; Kozubski W; Michalak S
Rev Neurosci; 2018 Sep; 29(7):745-755. PubMed ID: 29561731
[TBL] [Abstract][Full Text] [Related]
12. Immune therapy in autoimmune encephalitis: a systematic review.
Nosadini M; Mohammad SS; Ramanathan S; Brilot F; Dale RC
Expert Rev Neurother; 2015; 15(12):1391-419. PubMed ID: 26559389
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
14. Thymoma and Autoimmune Encephalitis: Clinical Manifestations and Antibodies.
Guasp M; Landa J; Martinez-Hernandez E; Sabater L; Iizuka T; Simabukuro M; Nakamura M; Kinoshita M; Kurihara M; Kaida K; Bruna J; Kapetanovic S; Sánchez P; Ruiz-García R; Naranjo L; Planagumà J; Muñoz-Lopetegi A; Bataller L; Saiz A; Dalmau J; Graus F
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34301822
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic disorders of the CNS and autoimmune synaptic encephalitis.
Rosenfeld MR; Dalmau JO
Continuum (Minneap Minn); 2012 Apr; 18(2):366-83. PubMed ID: 22810133
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
[TBL] [Abstract][Full Text] [Related]
17. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case.
Jarius S; Metz I; König FB; Ruprecht K; Reindl M; Paul F; Brück W; Wildemann B
Mult Scler; 2016 Oct; 22(12):1541-1549. PubMed ID: 26869529
[TBL] [Abstract][Full Text] [Related]
18. [Paraneoplastic neurologic syndromes: laboratory diagnostics and immunological aspects].
Hayden Z; Böröcz K; Csizmadia Z; Kellermayer Z; Balogh P; Berki T
Magy Onkol; 2019 Sep; 63(3):261-267. PubMed ID: 31533147
[TBL] [Abstract][Full Text] [Related]
19. Paraneoplastic neurological syndromes.
Graus F; Dalmau J
Curr Opin Neurol; 2012 Dec; 25(6):795-801. PubMed ID: 23041955
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
